Next 10 |
(NewsDirect) Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer. These countries, including Romania and Israel, seem to have acknowledged Namodenoson...
(NewsDirect) The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up. Psoriasis is a chronic inflammatory skin disease caused by genetic disposition or environmental factors and is a burgeoning $16 b...
Community First Bancshares, Inc. (the “Company”), the stock holding company of Newton Federal Bank (the “Bank”), announced today that it has received all required regulatory approvals for the conversion of Community First Bancshares, MHC (the “MHC ...
Community First Bancshares, Inc. (the “Company”), the stock holding company of Newton Federal Bank (the “Bank”), announced today that, at a special meeting held on January 12, 2021, the members of Community First Bancshares, MHC (the “MHC”) appr...
Community First Bancshares, Inc. (the “Company”), the stock holding company of Newton Federal Bank (the “Bank”), announced today that Affinity Bancshares, Inc., a newly formed Maryland corporation that is the proposed successor holding company of the Bank (...
Community First Bancshares, Inc. (the “Company”) (Nasdaq:CFBI), the holding company for Newton Federal Bank (the “Bank”), announced today that its Board of Directors, together with the Board of Directors of Community First Bancshares, MHC (the “MHC”),...
Community First Bancshares, Inc. (NASDAQ: CFBI) (“CFBI”), the parent company of Newton Federal Bank, announced today that it has successfully completed its merger with ABB Financial Group, Inc. (“ABB”), parent company of Affinity Bank, effective the close of busine...
Cannabinoids bind to A3AR, the target of Can-Fite’s drugs Can-Fite’s unparalleled expertise in these targets will be utilized to develop new cannabis-based pharmaceuticals The transaction involves technology exchange, co-development, and revenue share on CBD-ba...
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver and inflammatory diseases, announced today the Company’s CEO Dr....
Upfront payments received from licensing deals in South Korea for Piclidenoson and Namodenoson with upfront and milestone payments of up to $10 million plus transfer pricing Preparatory work for an End of Phase II meeting with FDA to initiate Phase III study in liver can...
News, Short Squeeze, Breakout and More Instantly...
Community First Bancshares Inc. Company Name:
CFBI Stock Symbol:
NASDAQ Market:
(NewsDirect) Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer. These countries, including Romania and Israel, seem to have acknowledged Namodenoson...
(NewsDirect) The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up. Psoriasis is a chronic inflammatory skin disease caused by genetic disposition or environmental factors and is a burgeoning $16 b...
Community First Bancshares, Inc. (the “Company”), the stock holding company of Newton Federal Bank (the “Bank”), announced today that it has received all required regulatory approvals for the conversion of Community First Bancshares, MHC (the “MHC ...